The effect of early intravenous esmolol on myocardial protection after direct PCI in patients with acute ST-segment elevation myocardial infarction

The effect of early intravenous esmolol on myocardial protection after direct PCI in patients with acute ST-segment elevation myocardial infarction: single-center, randomized, single-blind, placebo-controlled clinical trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100045516

Enrollment

Unknown

Registered

2021-04-18

Start date

2021-06-01

Completion date

Unknown

Last updated

2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myocardial infarction

Interventions

Experimental group:Esmolol injection 2ml: 0.2g

Control group:Placebo group, 0.9% sodium chloride injection

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Aged > 18 years; 2.The onset of attack of infarct chest pain was less than 24 hours; 3.Acute anterior ST-segment elevation myocardial infarction after direct PCI; 4.Conventional ECG ST segment elevation >= 0.2mV in 2 or more adjacent thoracic leads, or new left bundle branch block; 5.Voluntarily participate in the study and have signed the informed consent.

Exclusion criteria

Exclusion criteria: 1.Suffered from life-threatening condition due to STEMI; 2.Patients have prolonged CPR (more than 20 minutes); 3.Patients with significant heart failure (Killip grade 3 or above); 4.Definite mechanical complications (including ventricular septal perforation, or rupture of the tendon bundle of the nipple, or ongoing or rupture of the left ventricular free wall); 5.Blood pressure = 5 ULN (Upper Limit of Normal), Cr> 134µmol/L (2mg/dl) or eGFR < 45ml/min/1.73m^2]; 13.Severe chronic obstructive pulmonary disease (COPD),bronchial asthma and respiratory failure; 14.Severe infection; 15.Severe weakness, such as bad liquid quality; 16.Neuropsychiatric diseases; 17.Malignant tumor; 18.Other pathophysiological conditions with an expected survival period of less than 6 months; 19.People who are allergic to the drug ingredients in this study; 20.Pregnant or lactating women; 21.Patients with contraindications for CMR examination (including magnetic metals or claustrophobia); 22.People suffering from other diseases that are not suitable for participating in clinical studies.

Design outcomes

Primary

Measure	Time frame
Cardiac magnetic resonance (CMR) myocardial infarction quality (%);Major adverse cardiac and cerebrovascular event(MACCE);	—

Secondary

Measure	Time frame
Area under the Curve (AUC) of creatine kinase isoenzyme (CK-MB);Area under the curve of cardiac troponin I;Left ventricular ejection;Quality of microvascular obstruction (%);Quality of internal myocardial bleeding (%);2.5 peak values of CK-MB and cTn I ;ST-segment regression degree of ELECTROcardiogram (%);Myocardial recovery index (%);Edema quality (%);Left ventricular end-diastolic volume;Left ventricular end-systolic volume;Single end point events (including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, emergency revascularization, and hospitalization for heart failure);	—

Measure

Time frame

Area under the Curve (AUC) of creatine kinase isoenzyme (CK-MB);Area under the curve of cardiac troponin I;Left ventricular ejection;Quality of microvascular obstruction (%);Quality of internal myocardial bleeding (%);2.5 peak values of CK-MB and cTn I ;ST-segment regression degree of ELECTROcardiogram (%);Myocardial recovery index (%);Edema quality (%);Left ventricular end-diastolic volume;Left ventricular end-systolic volume;Single end point events (including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, emergency revascularization, and hospitalization for heart failure);

—

Countries

China

Contacts

Public ContactYang Shuhan

Xinxiang Central Hospital

zhoukoyang@126.com+86 18336089638

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026